Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Anthony Peter Adamis, M.D.

TitleLecturer on Ophthalmology
InstitutionMassachusetts Eye and Ear Infirmary
DepartmentOphthalmology
AddressMassachusetts Eye & Ear Infrm
Ophthalmology
243 Charles St
Boston MA 02114
Phone212/408-0450

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug; 118(8):1594-602.
    View in: PubMed
  2. Karagianni N, Adamis AP. The case for complement and inflammation in AMD: open questions. Adv Exp Med Biol. 2010; 703:1-7.
    View in: PubMed
  3. Zahn G, Volk K, Lewis GP, Vossmeyer D, Stragies R, Heier JS, Daniel PE, Adamis AP, Chapin EA, Fisher SK, Holz FG, Löffler KU, Knolle J. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci. 2010 Feb; 51(2):1028-35.
    View in: PubMed
  4. Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP, Knolle J. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 2009 Oct; 127(10):1329-35.
    View in: PubMed
  5. Adamis AP. The rationale for drug combinations in age-related macular degeneration. Retina. 2009 Jun; 29(6 Suppl):S42-4.
    View in: PubMed
  6. Adamis AP, Miller JW. Judah Folkman. Semin Ophthalmol. 2009 May-Jun; 24(3):128-9.
    View in: PubMed
  7. Wroblewski JJ, Wells JA, Adamis AP, Buggage RR, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Altaweel MM. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009 Apr; 127(4):374-80.
    View in: PubMed
  8. Ellenberg D, Shi J, Jain S, Chang JH, Ripps H, Brady S, Melhem ER, Lakkis F, Adamis A, Chen DF, Ellis-Behnke R, Langer RS, Strittmatter SM, Azar DT. Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation. Br J Ophthalmol. 2009 Sep; 93(9):1134-40.
    View in: PubMed
  9. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008 Dec; 92(12):1606-11.
    View in: PubMed
  10. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008 Apr; 30(2):65-84.
    View in: PubMed
  11. Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci. 2008 Feb; 49(2):662-70.
    View in: PubMed
  12. Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul-Aug; 11(4):563-74.
    View in: PubMed
  13. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007 Jul; 171(1):53-67.
    View in: PubMed
  14. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007 Sep; 114(9):1702-12.
    View in: PubMed
  15. Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, Ng YS. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007 Mar; 48(3):1212-8.
    View in: PubMed
  16. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007 Feb; 48(2):858-65.
    View in: PubMed
  17. Starita C, Patel M, Katz B, Adamis AP. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol. 2007; 39:122-48.
    View in: PubMed
  18. Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C. Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization. Mol Vis. 2006; 12:1243-9.
    View in: PubMed
  19. Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci. 2006 Oct; 1082:151-71.
    View in: PubMed
  20. Lu M, Adamis AP. Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am. 2006 Sep; 19(3):323-34.
    View in: PubMed
  21. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006 Sep; 113(9):1508.e1-25.
    View in: PubMed
  22. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006 Jun; 168(6):2036-53.
    View in: PubMed
  23. Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis. 2006; 12:532-80.
    View in: PubMed
  24. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006 Jun; 113(6):992-1001.e6.
    View in: PubMed
  25. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb; 5(2):123-32.
    View in: PubMed
  26. Adamis AP, Altaweel M, Bressler NM, Cunningham ET, Davis MD, Goldbaum M, Gonzales C, Guyer DR, Barrett K, Patel M. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006 Jan; 113(1):23-8.
    View in: PubMed
  27. Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005 Oct; 112(10):1747-57.
    View in: PubMed
  28. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005 Jun; 40(3):352-68.
    View in: PubMed
  29. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005 Feb-Mar; 25(2):111-8.
    View in: PubMed
  30. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30; 351(27):2805-16.
    View in: PubMed
  31. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004 Aug; 165(2):457-69.
    View in: PubMed
  32. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004 Sep; 18(12):1450-2.
    View in: PubMed
  33. Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004 Feb; 45(2):368-74.
    View in: PubMed
  34. Lu M, Adamis AP. Ocular delivery of angiostatic agents. Int Ophthalmol Clin. 2004; 44(3):41-51.
    View in: PubMed
  35. Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003 Oct; 44(10):4457-64.
    View in: PubMed
  36. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003 Aug 4; 198(3):483-9.
    View in: PubMed
  37. Ambati BK, Joussen AM, Kuziel WA, Adamis AP, Ambati J. Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea. 2003 Jul; 22(5):465-7.
    View in: PubMed
  38. Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, Ogura Y, Adamis AP. Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol. 2003 Jul; 163(1):253-9.
    View in: PubMed
  39. Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jun; 44(6):2743-9.
    View in: PubMed
  40. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003 Jun; 9(6):781-8.
    View in: PubMed
  41. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003 May; 44(5):2155-62.
    View in: PubMed
  42. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003 May-Jun; 48(3):257-93.
    View in: PubMed
  43. Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg. 2003 Apr; 237(4):530-5.
    View in: PubMed
  44. Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes. 2003 Mar; 52(3):829-37.
    View in: PubMed
  45. Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci. 2003 Feb; 44(2):590-3.
    View in: PubMed
  46. Kaji Y, Amano S, Usui T, Oshika T, Yamashiro K, Ishida S, Suzuki K, Tanaka S, Adamis AP, Nagai R, Horiuchi S. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 2003 Feb; 44(2):521-8.
    View in: PubMed
  47. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):290-9.
    View in: PubMed
  48. Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):117-23.
    View in: PubMed
  49. Ciardella AP, Donsoff IM, Guyer DR, Adamis A, Yannuzzi LA. Antiangiogenesis agents. Ophthalmol Clin North Am. 2002 Dec; 15(4):453-8.
    View in: PubMed
  50. Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LP. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003 Jan; 17(1):76-8.
    View in: PubMed
  51. Moore JE, McMullen TC, Campbell IL, Rohan R, Kaji Y, Afshari NA, Usui T, Archer DB, Adamis AP. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci. 2002 Sep; 43(9):2905-15.
    View in: PubMed
  52. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 2002 Aug; 120(8):1063-8.
    View in: PubMed
  53. Moore JE, McMullen CB, Mahon G, Adamis AP. The corneal epithelial stem cell. DNA Cell Biol. 2002 May-Jun; 21(5-6):443-51.
    View in: PubMed
  54. Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol. 2002 May; 160(5):1683-93.
    View in: PubMed
  55. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002 Apr; 86(4):363-5.
    View in: PubMed
  56. Götte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, Kirchhof B, Adamis AP, Bernfield M. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci. 2002 Apr; 43(4):1135-41.
    View in: PubMed
  57. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest. 2002 Mar; 109(6):805-15.
    View in: PubMed
  58. Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am. 2002 Mar; 15(1):69-79.
    View in: PubMed
  59. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002 Mar; 21(2):145-51.
    View in: PubMed
  60. Husain D, Ambati B, Adamis AP, Miller JW. Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am. 2002 Mar; 15(1):87-91.
    View in: PubMed
  61. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar; 120(3):338-46.
    View in: PubMed
  62. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002 Mar; 133(3):373-85.
    View in: PubMed
  63. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002 Feb; 160(2):501-9.
    View in: PubMed
  64. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döhmen S, Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002 Mar; 16(3):438-40.
    View in: PubMed
  65. Joussen AM, Huang S, Poulaki V, Camphausen K, Beecken WD, Kirchhof B, Adamis AP. In vivo retinal gene expression in early diabetes. Invest Ophthalmol Vis Sci. 2001 Nov; 42(12):3047-57.
    View in: PubMed
  66. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001 Sep; 42(10):2408-13.
    View in: PubMed
  67. Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J, D'Amato RJ, Kuo C, Adamis AP. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci. 2001 Aug; 42(9):1975-9.
    View in: PubMed
  68. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001 Mar; 158(3):1161-72.
    View in: PubMed
  69. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001 Mar; 42(3):789-94.
    View in: PubMed
  70. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001 Jan; 158(1):147-52.
    View in: PubMed
  71. Afshari NA, Mullally JE, Afshari MA, Steinert RF, Adamis AP, Azar DT, Talamo JH, Dohlman CH, Dryja TP. Survey of patients with granular, lattice, avellino, and Reis-Bücklers corneal dystrophies for mutations in the BIGH3 and gelsolin genes. Arch Ophthalmol. 2001 Jan; 119(1):16-22.
    View in: PubMed
  72. Moromizato Y, Stechschulte S, Miyamoto K, Murata T, Tsujikawa A, Joussen AM, Adamis AP. CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. Am J Pathol. 2000 Oct; 157(4):1277-81.
    View in: PubMed
  73. Shiuey Y, Ambati BK, Adamis AP. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000 Aug; 107(8):1512-7.
    View in: PubMed
  74. Hofman P, Blaauwgeers HG, Tolentino MJ, Adamis AP, Nunes Cardozo BJ, Vrensen GF, Schlingemann RO. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res. 2000 Aug; 21(2):637-45.
    View in: PubMed
  75. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000 May; 156(5):1733-9.
    View in: PubMed
  76. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1186-91.
    View in: PubMed
  77. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1153-8.
    View in: PubMed
  78. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, Kim I, Delori FC, Adamis AP. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1181-5.
    View in: PubMed
  79. Tolentino MJ, Husain D, Theodosiadis P, Gragoudas ES, Connolly E, Kahn J, Cleland J, Adamis AP, Cuthbertson A, Miller JW. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000 Jan; 118(1):78-84.
    View in: PubMed
  80. Alexandrakis G, Filatov V, Adamis AP. Denovo development of corneal guttae and Fuchs' dystrophy in corneal grafts. CLAO J. 2000 Jan; 26(1):44-6.
    View in: PubMed
  81. Lu M, Amano S, Miyamoto K, Garland R, Keough K, Qin W, Adamis AP. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci. 1999 Dec; 40(13):3281-6.
    View in: PubMed
  82. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999 Sep 14; 96(19):10836-41.
    View in: PubMed
  83. Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999 Aug; 40(9):2115-21.
    View in: PubMed
  84. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999 Jul; 40(8):1808-12.
    View in: PubMed
  85. Ghiso N, Rohan RM, Amano S, Garland R, Adamis AP. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci. 1999 May; 40(6):1033-9.
    View in: PubMed
  86. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999; 3(1):9-14.
    View in: PubMed
  87. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998 Nov-Dec; 43(3):245-69.
    View in: PubMed
  88. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998 Mar 15; 101(6):1219-24.
    View in: PubMed
  89. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998 Feb; 105(2):232-7.
    View in: PubMed
  90. Yoo SH, Adamis AP. Retinal manifestations of aging. Int Ophthalmol Clin. 1998; 38(1):95-101.
    View in: PubMed
  91. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998 Jan; 39(1):18-22.
    View in: PubMed
  92. Tolentino MJ, Adamis AP. Angiogenic factors in the development of diabetic iris neovascularization and retinopathy. Int Ophthalmol Clin. 1998; 38(1):77-94.
    View in: PubMed
  93. An BB, Adamis AP. Chlamydial ocular diseases. Int Ophthalmol Clin. 1998; 38(1):221-30.
    View in: PubMed
  94. Pournaras CJ, Miller JW, Gragoudas ES, Husain D, Munoz JL, Tolentino MJ, Kuroki M, Adamis AP. Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol. 1997 Dec; 115(12):1553-8.
    View in: PubMed
  95. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997 Oct; 46(10):1619-26.
    View in: PubMed
  96. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997 Mar; 13(1):37-50.
    View in: PubMed
  97. Baum TD, Adamis AP, Jakobiec FA. Primary acquired melanosis of the conjunctiva. Int Ophthalmol Clin. 1997; 37(4):61-72.
    View in: PubMed
  98. Nicaeus TE, Tolentino MJ, Adamis AP, Rubin PA. Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro. Ophthal Plast Reconstr Surg. 1996 Dec; 12(4):235-9.
    View in: PubMed
  99. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996 Nov; 103(11):1820-8.
    View in: PubMed
  100. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996 Oct 1; 98(7):1667-75.
    View in: PubMed
  101. Loughman MS, Chatzistefanou K, Gonzalez EM, Flynn E, Adamis AP, Shing Y, D'Amato RJ, Folkman J. Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol. 1996 Aug; 24(3):289-95.
    View in: PubMed
  102. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996 Aug; 114(8):964-70.
    View in: PubMed
  103. Shima DT, Gougos A, Miller JW, Tolentino M, Robinson G, Adamis AP, D'Amore PA. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci. 1996 Jun; 37(7):1334-40.
    View in: PubMed
  104. Huang SH, Adamis AP, Wiederschain DG, Shima DT, Shing Y, Moses MA. Matrix metalloproteinases and their inhibitors in aqueous humor. Exp Eye Res. 1996 May; 62(5):481-90.
    View in: PubMed
  105. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem. 1996 Feb 16; 271(7):3877-83.
    View in: PubMed
  106. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996 Jan; 114(1):66-71.
    View in: PubMed
  107. Durand M, Adamis A, Baker AS. Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Curr Clin Top Infect Dis. 1996; 16:125-50.
    View in: PubMed
  108. D'Amato RJ, Adamis AP. Angiogenesis inhibition in age-related macular degeneration. Ophthalmology. 1995 Sep; 102(9):1261-2.
    View in: PubMed
  109. Adamis AP, D'Amato RJ. Shedding light on diabetic retinopathy. Ophthalmology. 1995 Aug; 102(8):1127-8.
    View in: PubMed
  110. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'Amore PA. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995 Jan; 1(2):182-93.
    View in: PubMed
  111. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994 Oct 15; 118(4):445-50.
    View in: PubMed
  112. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep; 145(3):574-84.
    View in: PubMed
  113. Lucarelli MJ, Adamis AP. Avellino corneal dystrophy. Arch Ophthalmol. 1994 Mar; 112(3):418-9.
    View in: PubMed
  114. Navon SE, Adamis AP. Safety during the transition to phacoemulsification: a survey. Int Ophthalmol Clin. 1994; 34(3):51-65.
    View in: PubMed
  115. Adamis AP, Filatov V, Tripathi BJ, Tripathi RC. Fuchs' endothelial dystrophy of the cornea. Surv Ophthalmol. 1993 Sep-Oct; 38(2):149-68.
    View in: PubMed
  116. Adamis AP, Shima DT, Yeo KT, Yeo TK, Brown LF, Berse B, D'Amore PA, Folkman J. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993 Jun 15; 193(2):631-8.
    View in: PubMed
  117. Adamis AP, Schein OD, Kenyon KR. Anterior corneal disease of epidermolysis bullosa simplex. Arch Ophthalmol. 1993 Apr; 111(4):499-502.
    View in: PubMed
  118. Kowal VO, Adamis AP, Albert DM. Conjunctival concretions. Am J Ophthalmol. 1992 Nov 15; 114(5):640-1.
    View in: PubMed
  119. Guyer DR, Adamis AP, Gragoudas ES, Folkman J, Slakter JS, Yannuzzi LA. Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa? Arch Ophthalmol. 1992 Oct; 110(10):1383-4.
    View in: PubMed
  120. Bilyk JR, Adamis AP, Mulliken JB. Treatment options for periorbital hemangioma of infancy. Int Ophthalmol Clin. 1992; 32(3):95-109.
    View in: PubMed
  121. Adamis AP, Meklir B, Joyce NC. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol. 1991 Nov; 139(5):961-7.
    View in: PubMed
  122. Adamis AP, Molnar ML, Tripathi BJ, Emmerson MS, Stefansson K, Tripathi RC. Neuronal-specific enolase in human corneal endothelium and posterior keratocytes. Exp Eye Res. 1985 Nov; 41(5):665-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Adamis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (536) concept(s)
_
Co-Authors
See all (38) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_